North Central Cancer Treatment Group

North Central Cancer Treatment Group
Name	North Central Cancer Treatment Group
Formation	1977
Dissolved	2015 (merged)
Type	Clinical trials cooperative group
Headquarters	Chicago, Illinois
Region served	United States
Leader title	Director

North Central Cancer Treatment Group The North Central Cancer Treatment Group was a cooperative clinical trials organization focused on oncology research, conducting multicenter studies across the United States and partnering with academic centers, community hospitals, and government agencies. It coordinated randomized trials, translational research, and practice-changing investigations in collaboration with national organizations and regional cancer centers. The group contributed to study design, patient accrual, data analysis, and dissemination that influenced oncology practice, guideline committees, and regulatory decisions.

History

Founded in 1977, the consortium emerged amid an era of expanding cooperative research exemplified by groups such as National Cancer Institute consortia, the Southwest Oncology Group, the Eastern Cooperative Oncology Group, and the Cancer and Leukemia Group B. Early leaders connected to institutions like Mayo Clinic, University of Minnesota, and Northwestern University guided protocol development and site activation. Through the 1980s and 1990s the group expanded accrual networks to include academic centers such as University of Chicago Medicine, University of Iowa Hospitals and Clinics, and community systems modeled on collaborations with Community Clinical Oncology Program sites. Regulatory shifts initiated by the Food and Drug Administration and funding realignments influenced cooperative group consolidation, leading to organizational changes culminating in a 2015 merger with other cooperative entities that mirrored broader reorganizations involving National Clinical Trials Network partners.

Organization and Membership

The group operated as a cooperative overseen by a steering committee, protocol chairpersons, biostatistics cores, and institutional principal investigators drawn from academic medical centers including Cleveland Clinic, Mayo Clinic Hospital, University of Wisconsin Hospital and Clinics, and regional cancer centers such as Fox Chase Cancer Center and Masonic Cancer Center. Membership encompassed principal investigators from universities like Indiana University School of Medicine, community leaders affiliated with Northwestern Memorial Hospital, and research nurses from institutions like Johns Hopkins Hospital. The organizational model aligned with governance structures seen in National Institutes of Health-supported consortia, featuring data coordinating centers, institutional review boards from institutions such as University of Minnesota Institutional Review Board and quality assurance partnerships with groups like Radiological Physics Center.

Research Programs and Clinical Trials

The group ran therapeutic, supportive care, and translational trials across malignancies including breast cancer, colorectal cancer, lung cancer, lymphoma, and leukemia. Trial portfolios included Phase II and Phase III randomized protocols comparing chemotherapeutic regimens from agents like doxorubicin, cisplatin, and targeted agents paralleling development paths of drugs evaluated by European Organisation for Research and Treatment of Cancer investigators. It coordinated surgical oncology trials aligning with practices at Memorial Sloan Kettering Cancer Center and radiation oncology studies with partners such as MD Anderson Cancer Center. Collaborative trials were submitted to oversight bodies including the National Cancer Institute Cancer Therapy Evaluation Program and monitored via safety boards associated with Data and Safety Monitoring Board practices.

Major Contributions and Key Studies

Significant publications from the group influenced management of early-stage breast cancer adjuvant therapy, adjuvant strategies in colorectal cancer mirroring work by American Society of Clinical Oncology panels, and chemoradiation sequencing in non-small cell lung cancer consistent with trials from International Association for the Study of Lung Cancer. Pivotal randomized studies evaluated combinations that informed practice guidelines by organizations such as National Comprehensive Cancer Network committees and contributed data to meta-analyses published in journals linked to American Association for Cancer Research and Journal of Clinical Oncology. Translational correlative studies incorporated biomarkers later referenced in consensus statements from groups like College of American Pathologists and molecular profiling initiatives akin to projects at The Cancer Genome Atlas.

Funding and Collaborations

Funding sources included grants from the National Cancer Institute, cooperative agreements with federal programs, and partnerships with philanthropic organizations such as American Cancer Society chapters and regional foundations like Mayo Clinic Cancer Center Fund. Industry collaborations for agent supply and correlative studies involved pharmaceutical companies that also supported trials within the Clinical Trials Cooperative Group Program. Multi-institutional collaborations extended to international partners and consortia models exemplified by cooperation with centers engaged in European Society for Medical Oncology activities and data-sharing efforts comparable to Translational Research Working Group initiatives.

Impact on Clinical Practice and Guidelines

Results from the group’s trials were incorporated into guideline updates by bodies such as the National Comprehensive Cancer Network, American Society of Clinical Oncology, and specialty societies influencing surgical guidance by Society of Surgical Oncology and radiation recommendations from American Society for Radiation Oncology. Practice-changing evidence from randomized protocols affected chemotherapy sequencing, supportive care approaches endorsed by Oncology Nursing Society, and survivorship care recommendations echoed in Institute of Medicine reports. Data contributed to systematic reviews used by payer and policy stakeholders including panels convened by U.S. Preventive Services Task Force-style committees and informed educational curricula at institutions like University of Chicago Pritzker School of Medicine.

Category:Oncology research organizations